KRAS and neoplasm: Allograft tumours derived from APC/KRAS/PTEN spheres were also sensitive to sequential treatment: strikingly, three of five allograft tumours showed regression in response to 0.01 mg kg−1 bortezomib followed by BEZ235 (Fig. 10c).